Cardlytics, Inc. (NASDAQ:CDLX) Receives $6.92 Consensus Target Price from Analysts

Cardlytics, Inc. (NASDAQ:CDLX) has been assigned a consensus rating of “Hold” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $6.92.

Several equities analysts have commented on the stock. Evercore ISI initiated coverage on shares of Cardlytics in a report on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price on the stock. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th.

Insider Activity at Cardlytics

In other news, CFO Alexis Desieno sold 25,118 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the transaction, the chief financial officer now owns 116,481 shares of the company’s stock, valued at $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the sale, the chief executive officer now owns 178,519 shares in the company, valued at approximately $687,298.15. This represents a 11.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,007 shares of company stock valued at $251,297 in the last quarter. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CDLX. Geode Capital Management LLC increased its holdings in Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after purchasing an additional 73,484 shares during the period. Marshall Wace LLP grew its position in shares of Cardlytics by 6.8% in the 2nd quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock valued at $6,685,000 after buying an additional 52,081 shares during the last quarter. RBF Capital LLC increased its stake in shares of Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after buying an additional 369,620 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Cardlytics by 3.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock worth $1,249,000 after acquiring an additional 11,388 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its stake in shares of Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after acquiring an additional 354,474 shares during the period. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Trading Down 6.6 %

Shares of NASDAQ:CDLX opened at $3.13 on Friday. The business’s 50 day simple moving average is $3.85 and its 200 day simple moving average is $4.70. Cardlytics has a 1 year low of $2.89 and a 1 year high of $20.52. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The company has a market capitalization of $159.07 million, a P/E ratio of -0.51 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.18. The company had revenue of $67.06 million for the quarter, compared to analyst estimates of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. Cardlytics’s quarterly revenue was down 15.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.26) EPS. On average, research analysts anticipate that Cardlytics will post -1.52 EPS for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.